vadastuximab talirine
mAbexperimentalADC
Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML). — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01902329)
Timeline
Indications
Mechanism of action
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- pyrrolobenzodiazepine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVadastuximab talirine ↗
- ChEMBLCHEMBL3990021 ↗
Also known as
- sgn-cd33a
- sgn-cd33a
- vadastuximab talirine
- vadastuximab talirine
- vadastuximab talirine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02785900 | Phase 3 | May 1, 2016 | Seattle Genetics |
| NCT02706899 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Seattle Genetics |
| NCT02614560 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Seattle Genetics |
| NCT02326584 | Phase 1 | Dec 1, 2014 | Seattle Genetics |
| NCT01902329 | Phase 1 | Jul 1, 2013 | Seattle Genetics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seattle Genetics | For profit | 5 | 5 | 3 | 2013 |
1 organizations
Page 1 / 1